PPARγ ligands, like glitazones, are clinically used to treat type 2 diabetes as insulin-sensitizing drugs and PPARα ligands, like fibrates, are used to manage elevated blood lipid levels and type 2 diabetes as hypolipidemic agents. This evidence concerns the gene INS and type 2 diabetes mellitus.